**Venu Holding Corporation Announces Resignation of Director and Termination of Agreement**

Venu Holding Corporation, listed on NYSE American under the symbol VENU, recently filed a Form 8-K with the Securities and Exchange Commission on January 27, 2025. The filing reveals important corporate updates, including the resignation of a board member and the termination of a key agreement.

Chad Hennings, a member of the board of directors at Venu Holding Corporation, tendered his resignation on January 27, 2025. The resignation did not stem from any disagreement relating to the company’s operations, policies, or practices. Following Hennings’ departure, the Company provided notice to terminate the Marketing and Consulting Services Agreement that was in place with Mr. Hennings. This Agreement, initiated on January 25, 2023, involved Mr. Hennings providing services as a spokesperson and business-development promoter in exchange for compensation of $60,000 in cash annually, along with a warrant exercisable to purchase shares of the Company’s common stock. The termination of the Agreement did not result in any significant early termination penalties for Venu Holding Corporation.

As an emerging growth company, Venu Holding Corporation has not opted for an extended transition period for compliance with new or revised financial accounting standards. The company’s common stock is listed on NYSE American, and its activities are overseen by Chief Executive Officer and Chairman, J.W. Roth.

The filing also provides information on the acquisition activities of OS Therapies, a notable entity in the biotechnology industry. OS Therapies recently announced an agreement to acquire listeria monocytogenes-based immuno-oncology programs and related intellectual property assets from Ayala Pharmaceuticals. This acquisition brings additional assets to OS Therapies’ pipeline, including Phase 2 lung cancer and Phase 1 prostate cancer programs.

The filing further elucidates that OS Therapies has entered into a financing agreement to support these acquisitions, with the anticipation of submitting a Biologics Licensing Application (BLA) for OST-HER2 in osteosarcoma later in 2025. The company plans to request a Priority Review Voucher (PRV) from the FDA upon approval of the BLA.

Such strategic moves in the biotechnology domain, as mentioned in the exhibit attached to Venu’s filing, reflect the dynamic nature of the healthcare sector. Venu Holding Corporation continues to position itself within the financial and regulatory landscape to navigate these changes effectively.

This news highlights Venu Holding Corporation’s ongoing corporate developments and the broader industry trends impacting the biotechnology sector.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Venu’s 8K filing here.

Venu Company Profile

Venu Holding Corporation is a premier hospitality and live music company dedicated to crafting luxury, experience-driven entertainment destinations. Venu Holding Corporation is based in COLORADO SPRINGS, Colo.